Company intelligence / Profile preview
Plureon
Winston-Salem, North Carolina, United States
- Ownership
- Private
- Development stage
- Other
01
Overview
Plureon was a biotechnology company focused on the development of regenerative medicine therapies using Multipotent Adult Progenitor Cells (MAPCs). The company was established to commercialize the breakthrough discovery of MAPCs, which are adult-derived stem cells capable of differentiating into multiple cell lineages, similar to embryonic stem cells but without the associated ethical concerns. Plureon's research targeted a broad spectrum of indications, including cardiovascular, neurological, and musculoskeletal disorders. In 2003, the company was acquired by Athersys, which subsequently advanced the MAPC technology under the brand name MultiStem.
- Therapeutic areas
- RheumatologyCardiovascularImmunologyNeurology
- Modalities
- Stem cell therapyCell therapy
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
University of Minnesota
Beyond the preview
Go deeper on Plureon.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Plureon.